Latest news with #Matuszewski
Business Insider
7 days ago
- Business
- Business Insider
Jefferies Keeps Their Buy Rating on Wayfair (W)
In a report released today, Jonathan Matuszewski from Jefferies maintained a Buy rating on Wayfair, with a price target of $74.00. The company's shares closed today at $73.48. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Matuszewski is a 4-star analyst with an average return of 5.4% and a 50.25% success rate. Matuszewski covers the Consumer Cyclical sector, focusing on stocks such as Williams-Sonoma, Wayfair, and Lowe's. In addition to Jefferies, Wayfair also received a Buy from William Blair's Phillip Blee in a report issued today. However, on the same day, Wedbush maintained a Hold rating on Wayfair (NYSE: W). W market cap is currently $8.37B and has a P/E ratio of -22.81. Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of W in relation to earlier this year.
Yahoo
28-05-2025
- Business
- Yahoo
BioStem Announces Notice of Allowance for Three New U.S. Patent Applications
Expanding patent portfolio reinforces the Company's commitment to wound care innovation, with 55 issued patents and 52 pending applications POMPANO BEACH, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for two design patents and one utility patent covering the Company's novel fenestrated human placental allograft designs and compositions manufactured using the BioREtain® process. The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for BioStem's Design Patent Application No. 29/860,417 for FENESTRATED HUMAN PLACENTAL ALLOGRAFT and for Design Patent Application No. 29/860,420 for FENESTRATED HUMAN PLACENTAL ALLOGRAFT. These patents pertain to novel and inventive fenestrated human placental allograft designs manufactured using the BioREtain process. The unique design allows wound exudate to pass through the graft and away from the wound without sacrificing allograft area, thereby facilitating drainage and providing an environment that is more conducive to healing. Additionally, the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for BioStem's Patent Application No. 18/926,867 for STERILE HUMAN PLACENTAL ALLOGRAFTS HAVING A PLURALITY OF SLITS, OPENINGS, AND/OR FENESTRATIONS FORMED THEREON. This patent pertains to novel and inventive fenestrated human placental allograft compositions manufactured using the BioREtain process with a unique fenestration that allows wound exudate to pass through the graft and away from the wound without sacrificing allograft area. The method of preparation preserves the structural and molecular integrity of the amnion and chorion tissues, thereby facilitating and enhancing wound treatment compared to conventional human placental allografts, particularly in the treatment of diabetic foot ulcers, dental wounds, and other topical Matuszewski, Chief Executive Officer of BioStem Technologies, commented: 'BioStem is actively expanding its patent portfolio to accelerate product innovation and drive the development of new products that elevate the standard of wound care. These newly granted patents play a pivotal role in the advancement of our next-generation placental allograft technologies and underscore the proprietary nature of our BioREtain process - designed to preserve the structural and molecular integrity of the placental tissue. By optimizing the retention and preservation of the amnion, intermediate, and chorion layers, we are able to offer clinicians solutions that support better outcomes and improve patient care. This continued innovation further solidifies BioStem's leadership in advanced wound care.' Join BioStem's Distribution List & Social Media: To follow the latest developments at BioStem, sign-up to the Company's email distribution list HERE, and follow us on X and LinkedIn. About BioStem Technologies, Inc. (OTC: BSEM):BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ('AATB'). These systems and procedures are established per current Good Tissue Practices ('cGTP') and current Good Manufacturing Processes ('cGMP'). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit and follow us on X and LinkedIn. Forward-Looking Statements:Except for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as 'forecast,' 'intend,' 'seek,' 'target,' 'anticipate,' 'believe,' 'expect,' 'estimate,' 'plan,' 'outlook,' and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company's products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company's products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete;(4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company's ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company's ability to maintain production of its products in sufficient quantities to meet demand; and (10) the COVID-19 pandemic and its impact, if any, on the Company's fiscal condition and results of operations; You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Contact BioStem Technologies, Inc.:Phone: 954-380-8342Website: info@ @BSEM_TechFacebook: BioStemTechnologies Investor Relations:Adam HoldsworthE-Mail: adam@ 917-497-9287
Yahoo
12-05-2025
- Business
- Yahoo
BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results
Preliminary net revenue increased 73% to $72.5 million for Q1 2025, compared to $41.9 million in Q1 2024 Achieved preliminary GAAP net income of $4.5 million, or $0.27 per share Reported preliminary Q1 2025 Adjusted EBITDA of $7.8 million Quarter-end cash balance of $26.7 million, up from $22.8 million as of December 31, 2024 Financial results conference call and webcast to be held on May 12, 2025 at 4:30 pm ET POMPANO BEACH, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (the 'Company' or 'BioStem'), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics, today reported preliminary financial results for the first quarter ended March 31, 2025. The Company will host a webcast and conference call today at 4:30 pm ET. These results are unaudited, have been prepared in accordance with current accounting policies, and remain subject to SEC review related to the Company's pending Form 10 filing in connection with its planned uplisting to Nasdaq. Jason Matuszewski, CEO of BioStem, commented: 'I am pleased to report the strongest first quarter in BioStem's history, with Q1 2025 revenue increasing 73% compared to the first quarter of 2024. With the launch of Vendaje AC® in Q4 2024, we have seen rapid adoption of that product through our commercial partnership with Venture Medical. Furthermore, we are encouraged by the LCD implementation date being extended from April 2025 to January 2026, as the uncertainty throughout this quarter had created temporary headwinds that impacted our operations and sequential growth trajectory.' Mr. Matuszewski added: 'As we progress through Q2 and the rest of the year, we remain focused on continued growth and further strengthening our position in the chronic wound care market. Strategically, we are prioritizing the transition of more customers to Vendaje AC to drive brand consistency within the Vendaje family, while also reducing SG&A by phasing out licensing fees associated with AmnioWrap2. On the capital markets front, we remain in active review with the SEC regarding our Form 10 registration and uplisting process, and we look forward to completing this milestone and becoming listed on Nasdaq. We want to thank our shareholders for their continued support.' First Quarter 2025 and Recent Corporate Highlights: In Q1 2025, BioStem announced key milestones that further solidify its leadership in placental-derived products for wound care. The Company has received Institutional Review Board (IRB) approval to initiate a new clinical trial evaluating BioREtain® Amnion Chorion (BR-AC) for the treatment of venous leg ulcers (VLUs). This study is BioStem's third prospective clinical trial and reflects its ongoing commitment to building a robust body of clinical evidence that demonstrates superior patient outcomes and supports wider adoption of its advanced wound care solutions. BioStem also launched its BR-AM-DFU clinical trial to evaluate Vendaje®, the Company's proprietary amniotic membrane product, in the treatment of non-healing diabetic foot ulcers. This trial will evaluate Vendaje against the current standard of care, offering an opportunity to further validate the clinical efficacy of the BioREtain technology platform and accelerate commercial growth in the diabetic wound care segment. Additionally, BioStem has expanded its intellectual property portfolio with the U.S. Patent and Trademark Office. With a total of 55 patents that have been issued and 52 pending patents, the Company continues to reinforce its innovation leadership and lay the groundwork for the development of next-generation products in regenerative medicine and wound care. Summary Financial Information1: The following table represents preliminary net revenue, gross margin, operating expenses, and other expenses for the fourth quarter and year-to-date periods ended March 31, 2025, and March 31, 2024, respectively: Three months ended, March 31, 2025 March 31, 2024 $ Change % Change Net revenue $ 72,528,112 $ 41,904,213 $ 30,623,899 73 % Gross profit $ 71,674,674 $ 39,679,509 $ 31,995,165 81 % Gross profit % 99 % 95 % 4 % Operating expenses $ 66,425,350 $ 35,071,396 $ 31,353,953 89 % Operating income (loss) $ 5,249,325 $ 4,608,114 $ 641,211 14 % Other expense, net $ (766,229 ) $ (1,350,200 ) $ 583,971 -43 % Net income (loss) $ 4,483,096 $ 3,257,914 $ 1,225,182 38 % ________________________ 1 As will be discussed in more detail on the BioStem conference call, BioStem is currently going through an SEC review process in connection with its planned uplist to Nasdaq. The ongoing discussions with the SEC relate to the accounting treatment of the Bona Fide Service Fees (BFSF) paid to Venture, and the related impact to reported revenue, gross margin and operating expenses. All of the financial information provided herein, including in this Summary Financial Information, are unaudited, has been prepared consistent with the Company's current accounting policies and is subject to resolution of all SEC comments and completion of all closing and audit procedures which may cause actual results to differ materially from those presented in this press release. Financial Results for the Three Months Ended March 31, 2025: Net revenue for Q1 2025 was $72.5 million, a 73% increase compared to Q1 2024. The increase was driven by strong performance across the Company's wound care portfolio, led by VendajeAC, supported by expanded commercial coverage and sales force expansion. Gross profit was $71.7 million, or 99% of net revenue, compared to $39.7 million or 95% of net revenue in Q1 2024. The improvement reflects product mix benefits, scale efficiencies, and increased contributions from Vendaje AC, which does not incur licensing fees. Operating expenses totaled $66.4 million, up from $35.1 million in Q1 2024, primarily driven by increased sales and marketing costs associated with the Venture Medical distribution agreement. Adjusted EBITDA for the first quarter was $7.8 million, compared to $7.9 million in Q1 2024. The slight decline reflects higher gross profit being offset by increased operating expenses, including sales and marketing costs—primarily Bona Fide Service Fees tied to elevated sales volume—along with higher research and development expenses related to three active clinical trials, and increased general and administrative costs driven by expanded headcount as the company scales. GAAP net income was $4.5 million or $0.27 per share, compared to $3.3 million or $0.20 per share in Q1 2024. This marks BioStem's fifth consecutive quarter with positive GAAP net income. Quarter-end cash balance of $26.7 million, up from $22.8 million as of December 31, 2024. Conference Call & Webcast Information: Conference ID: 9695874 North America Toll-Free: (800) 715-9871 International Toll: +1 (646) 307-1963 Webcast Link: The live and archived webcast will be available on the BioStem Technologies website under the Investor Relations section, HERE. Join BioStem's Distribution List & Social Media: To follow the latest developments at BioStem, sign-up to the Company's email distribution list HERE, and follow us on X and LinkedIn. About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain ® processing method. BioREtain ® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ('AATB'). These systems and procedures are established per current Good Tissue Practices ('cGTP') and current Good Manufacturing Processes ('cGMP'). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE ® , VENDAJE AC ® , and VENDAJE OPTIC ® . Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit and follow us on X and LinkedIn. Preliminary Results: BioStem's financial results for the first quarter 2024 and 2025 included in this press release are preliminary, unaudited and subject to finalization of BioStem's audited financial statements for the year ended December 31, 2024 and resolution of all SEC comments on the Form 10 registration statement BioStem filed with the SEC in connection with its planned uplist to Nasdaq. These financial results should not be viewed as a substitute for final reviewed results prepared in accordance with U.S. generally accepted accounting principles ('GAAP'). The preliminary financial results represent management estimates that constitute forward-looking statements subject to risks and uncertainties. As a result, the preliminary financial results and other information provided herein may materially differ from the actual results that will be reflected in the consolidated audited financial statements for the year ended December 31, 2024 and unaudited financial statements for the first quarter ended March 31, 2025 and 2024 when they are completed and publicly disclosed. BioStem undertakes no obligation to update or supplement the information provided herein until it reports its final audited financial results for the year ended December 31, 2024. Forward-Looking Statements: Certain statements in this press release may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as 'forecast,' 'intend,' 'seek,' 'target,' 'anticipate,' 'believe,' 'expect,' 'estimate', 'plan,' 'outlook,' and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical fact. Forward-looking statements in this release include, among other things, statements regarding: the preliminary financial results for the first quarter 2025; the anticipated timing of current and planned clinical trials; the expectation that such trials will demonstrate the clinical superiority of the Company's products; the Company's expectations regarding its ability to uplist to Nasdaq; the Company's ability to resolve the SEC's comments to the Company's Form 10 registration statement; the Company's strategic initiatives; second quarter and full year 2025 projections; continued financial growth; and the market penetration of the Company's core products. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: the impact of any changes to the reimbursement levels for the Company's products; significant and continuing competition, which could adversely affect the Company's business, results of operations and financial condition; rapid technological change, which could cause the Company's products to become outdated or obsolete, harming the Company's ability to effectively compete; the Company's ability to convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; the Company's ability to obtain financing to expand its business; the Company has incurred significant losses since inception and may incur losses in the future; changes in applicable laws or regulations; the Company's ability to maintain production of its products in sufficient quantities to meet demand; and the effects of global and regional economic, political, social and health crises;. There may be additional risks about which the Company is presently unaware or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company undertakes no duty to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. BioStem Technologies, Inc.:Phone: 954-380-8342Website: info@ @BSEM_TechFacebook: BioStemTechnologies Investor Relations:Adam HoldsworthE-Mail: adam@ Phone: 917-497-9287BioStem Technologies, Inc. and Subsidiaries Consolidated Balance Sheets March 31, 2025 (Unaudited) December 31, 2024 (Unaudited) Current Assets Cash and cash equivalents $ 26,673,455 $ 22,832,706 Accounts receivable, net 109,657,309 104,980,085 Inventory 1,972,637 1,824,001 Short-term loan receivable 1,250,000 1,250,000 Prepaid expenses and other assets 2,479,457 2,874,317 Total current assets 142,032,858 133,761,109 Long-Term Assets Property and equipment, net 1,488,128 1,504,578 Construction-in-process 348,503 190,422 Right-of-use asset, net 247,104 271,214 Intangible assets, net 193,270 224,137 Goodwill 244,635 244,635 Deferred tax assets 4,759,016 4,179,632 Total assets $ 149,313,514 $ 140,375,727 Current Liabilities Accounts payable and accrued expenses $ 4,048,467 $ 5,289,787 License fees payable 443,850 2,359,575 Bona fide services fee payable 85,525,228 81,873,058 Income tax payable 4,285,551 2,908,730 Accrued interest 2,029,677 1,962,983 Operating lease liabilities 110,653 106,722 Notes payable, net of discount 3,894,122 3,957,744 Other current liabilities 1,155,591 711,361 Total current liabilities 101,493,139 99,169,960 Long-Term Liabilities Operating lease liabilities, less current portion 151,280 180,235 Notes payable, less current portion 150,000 150,000 Total long-term liabilities 301,280 330,235 Total liabilities 101,794,420 99,500,195 Commitments and contingencies (Note 8) Stockholders' Equity (Deficit) Series A-1 convertible preferred stock, $0.001 par value authorized, 300 shares; issued and outstanding, 300 shares as of December 31, 2024 and December 31, 2023. - - Series B-1 convertible preferred stock, $0.001 par value authorized, 500,000 shares; issued and outstanding 5 shares as of December 31, 2024 and December 31, 2023. - - Common stock, $0.001 par value authorized, 975,000,000 shares issued and outstanding 16,661,482 and 16,214,390 shares as of December 31, 2024 and December 31, 2023, respectively. 16,602 16,662 Additional paid-in capital 56,803,063 54,642,012 Treasury stock, 18,000 shares at cost (43,346 ) (43,346 ) Accumulated deficit (9,257,226 ) (13,739,796 ) Total stockholders' equity (deficit) 47,519,094 40,875,532 Total liabilities and stockholders' equity $ 149,313,514 $ 140,375,727 BioStem Technologies, Inc. and Subsidiaries Consolidated Statements of Operations Three-months ended, March 31, 2025 March 31, 2024 Revenue, net $ 72,528,112 $ 41,904,213 Cost of goods sold 853,438 2,224,704 Gross profit 71,674,674 39,679,509 Gross Margin % 98.8 % 94.7 % Operating Expenses Sales and marketing expenses 57,684,468 30,547,721 General and administrative expenses 6,994,004 4,399,262 Research and development expenses 1,690,154 70,748 Depreciation and amortization expense 56,723 53,665 Total operating expenses 66,425,350 35,071,396 Income (loss) from operations 5,249,325 4,608,114 Other income (expense): Interest expense, net 31,617 (163,942 ) Other expense (409 ) 1,571 Other income (expense), net 31,208 (165,513 ) Total Income (loss) from operations before income taxes 5,280,533 4,442,601 Income tax expense (797,437 ) (1,184,687 ) Net Income (loss) $ 4,483,096 $ 3,257,914 Basic net income (loss) per share attributable to common stockholders $ 0.27 $ 0.20 Diluted net income (loss) per share attributable to common stockholders $ 0.17 $ 0.15 Basic weighted average common shares outstanding 16,673,875 16,316,178 Diluted weighted average common shares outstanding 26,257,562 22,383,275 Non-GAAP Financial Measures Our management uses financial measures that are not in accordance with generally accepted accounting principles in the United States, or GAAP, in addition to financial measures in accordance with GAAP to evaluate our operating results. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP. Our management uses Adjusted EBITDA, which we calculate as net income less interest, taxes, depreciation and amortization and share-based compensation expense, to evaluate our operating performance and trends and make planning decisions. Our management believes Adjusted EBITDA helps identify underlying trends in our business that could otherwise be masked by the effect of the items that we exclude. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by our management in its financial and operational decision-making. The following is a reconciliation of GAAP net income (loss) to non-GAAP EBITDA and non-GAAP Adjusted EBITDA for each of the periods presented: Three months ended, March 31, 2025 March 31, 2024 $ Change % Change Net income $ 4,483,096 $ 3,257,914 $ 1,225,182 38 % Interest expense (31,617 ) 163,942 195,559 -119 % Depreciation and amortization 56,723 53,665 3,058 6 % Income Taxes 797,437 1,184,687 (387,250 ) -33 % EBITDA 5,305,639 4,660,208 645,431 14 % Share-based compensation 2,536,933 3,279,117 (742,184 ) -23 % Adjusted EBITDA $ 7,842,572 $ 7,939,325 $ (96,753 ) -1 % Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31-03-2025
- Business
- Yahoo
BioStem Announces Notice of Allowance for Two U.S. Patent Applications
Company continues to innovate and strengthen its patent portfolio with 43 issued patents and 26 pending for its advanced wound care technology POMPANO BEACH, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for two of BioStem's patent applications. Jason Matuszewski, Chief Executive Officer of BioStem, stated: 'BioStem is actively expanding its patent portfolio to accelerate product innovation and to drive development of new products that continue to elevate the standards of wound care. These newly granted patents will play a pivotal role in the development of next-generation products, further solidifying our position as a leader in the industry. BioStem's robust intellectual property portfolio spans the wound care landscape, providing strong protection as we continue to introduce breakthrough solutions to the market and consider other regulatory pathways to strengthen our product positioning." The USPTO has issued a Notice of Allowance for the following applications: No. 18/593,225: MICRONIZED COMPOSITIONS FOR WOUND HEALING PREPARED FROM INTACT HUMAN AMNION-CHORION TISSUE HAVING AN INTACT INTERMEDIATE SPONGY LAYER POSITIONED THERE BETWEEN The patent is directed to novel and inventive micronized human placental compositions for wound care. The unique method of preparing BioStem's compositions results in optimal retention of the structural and molecular profile of the amnion and chorion tissue. These compositions can be used to develop products for wound packing, treatment of wounds having irregular surfaces/boundaries, weeping wounds, and dental/ oral wounds. These micronized compositions could even be integrated into a therapeutic bandage to support healing of a topical wound. No. 18/290,914: STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF The patent is directed to novel and inventive human placental allograft compositions manufactured with the BioRetain® process. The unique method of preparing these allograft compositions results in optimal retention of the structural and molecular profile of the amnion and chorion tissue thereby facilitating and supporting wound treatment when compared with conventional human placental allografts for the treatment of, for example, diabetic foot ulcers, dental wounds, and/or other topical wounds. Mr. Matuszewski added: 'The added protection for our proprietary BioREtain processing method bolsters the differentiation of this technology in the marketplace. We also intend to demonstrate the benefits of those differences to patients with ongoing benchtop and clinical studies.' Join BioStem's Distribution List & Social Media: To follow the latest developments at BioStem, sign-up to the Company's email distribution list HERE, and follow us on X and LinkedIn. About BioStem Technologies, Inc. (OTC: BSEM):BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ('AATB'). These systems and procedures are established per current Good Tissue Practices ('cGTP') and current Good Manufacturing Processes ('cGMP'). Our portfolio of quality brands includes AmnioWrap2 ™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit and follow us on X and LinkedIn. Forward-Looking Statements:Except for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as 'forecast,' 'intend,' 'seek,' 'target,' 'anticipate,' 'believe,' 'expect,' 'estimate,' 'plan,' 'outlook,' and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company's products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company's products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete;(4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company's ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company's ability to maintain production of its products in sufficient quantities to meet demand; and (10) the COVID-19 pandemic and its impact, if any, on the Company's fiscal condition and results of operations; You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. BioStem Technologies, 954-380-8342 Website: info@ @BSEM_TechFacebook: BioStemTechnologies PCG AdvisoryAdam Holdsworth Phone: 917-497-9287 Email: adam@ in to access your portfolio
